Uploaded November 2026 | Updated November 2026, 21 hours ago
The National Drug Authority, in collaboration with the Ministry of Health and other partners, is seeking to strengthen the use of digital technologies in monitoring the safety of medicines, particularly those used in the treatment and care of people living with HIV.
The initiative aims to improve pharmacovigilance through clinical guidance and digital reporting systems to detect, monitor and prevent adverse drug reactions.
Speaking during a stakeholders' meeting in Entebbe, the Director of Product Safety at the National Drug Authority, Dr Helen Ndagije, expressed concern over the low reporting of adverse drug reactions in Africa.
She noted that Africa contributes only about two percent of adverse drug reaction reports submitted to the international database, a gap that continues to undermine efforts to monitor medicine safety.
The National Drug Authority, in collaboration with the Ministry of Health and other partners, is seeking to strengthen the use of digital technologies in monitoring the safety of medicines, particularly those used in the treatment and care of people living with HIV.
The initiative aims to improve pharmacovigilance through clinical guidance and digital reporting systems to detect, monitor and prevent adverse drug reactions.
Speaking during a stakeholders' meeting in Entebbe, the Director of Product Safety at the National Drug Authority, Dr Helen Ndagije, expressed concern over the low reporting of adverse drug reactions in Africa.
She noted that Africa contributes only about two percent of adverse drug reaction reports submitted to the international database, a gap that continues to undermine efforts to monitor medicine safety.










